ym 529 has been researched along with risedronic acid in 19 studies
| Studies (ym 529) | Trials (ym 529) | Recent Studies (post-2010) (ym 529) | Studies (risedronic acid) | Trials (risedronic acid) | Recent Studies (post-2010) (risedronic acid) |
|---|---|---|---|---|---|
| 140 | 23 | 71 | 1,318 | 290 | 487 |
| Protein | Taxonomy | ym 529 (IC50) | risedronic acid (IC50) |
|---|---|---|---|
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | 0.1104 | |
| Farnesyl pyrophosphate synthase | Leishmania donovani | 0.1699 | |
| Farnesyl diphosphate synthase | Toxoplasma gondii | 0.074 | |
| Farnesyl diphosphate synthase | Trypanosoma cruzi | 0.027 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 10 (52.63) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Martin, MB; Oldfield, E; Szabo, CM | 1 |
| Burzynska, A; Chan, JM; Colantino, A; Ghosh, S; Kafarski, P; Meints, G; Morita, CT; Oldfield, E; Raker, AM; Sanders, JM; Song, Y; Wang, H | 1 |
| Araujo, FG; Chan, JM; Ling, Y; Moreno, SN; Odeh, S; Oldfield, E; Sahota, G | 1 |
| Hall, P; Hudock, MP; Leon, A; Liu, L; Morita, CT; Oldfield, E; Puan, KJ; Studer, D; Yang, Y; Yin, F | 1 |
| Cao, R; Chang, TH; Chen, CK; Guo, RT; Hudock, MP; Jeng, WY; Ko, TP; Kuo, CJ; Liang, PH; Oldfield, E; Song, Y; Wang, AH; Yin, F; Zhang, Y | 1 |
| Axelson, J; Cao, R; Chang, SC; Chang, TH; Guo, RT; Hudock, MP; K-M Chen, C; Ko, TP; Kumar, A; Liang, PH; No, JH; Oldfield, E; Song, Y; Wang, AH; Zhang, Y | 1 |
| Bala, JL; Baron, RA; Błazewska, KM; Coxon, FP; Dunford, JE; Ebetino, FH; Kashemirov, BA; Kirsten, ML; Lundy, MW; Mallard-Favier, I; Marma, MS; McKenna, CE; Rogers, MJ; Rojas, J; Seabra, MC; Stewart, CA | 1 |
| Berghuis, AM; Chiu, W; Cho, H; De Schutter, JW; Gritzalis, D; Lacbay, CM; Lin, YS; Park, J; Tsantrizos, YS; Zielinski, M | 1 |
| Bhuiyan, NH; Holstein, SA; Varney, ML; Wiemer, DF | 1 |
| Barnett, BL; Deprèle, S; Ebetino, FH; Evdokimov, A; Hogan, JM; Kashemirov, BA; McKenna, CE | 1 |
| Matsumoto, T | 1 |
| Amagase, K; Inaba, A; Ishikawa, Y; Murakami, T; Nukui, K; Senta, T; Takeuchi, K | 1 |
| Amano, N; Honda, Y; Iwamoto, J; Sato, Y | 1 |
| Furuya, T; Hasegawa, M; Hirabayashi, H; Iwamoto, J; Kumakubo, T; Makita, K; Okano, H; Urano, T | 1 |
| Chen, X; Liu, C; Yang, Y; Zhang, Y; Zhong, D; Zhou, L | 1 |
| Ebina, K; Hashimoto, J; Hirao, M; Kaneshiro, S; Noguchi, T; Yoshikawa, H; Yukioka, M | 1 |
| Hyodo, K; Kamada, H; Mishima, H; Nishino, T; Nozawa, D; Yamazaki, M | 1 |
| Choe, H; Harigane, K; Inaba, Y; Kumagai, K; Kusayama, Y; Saito, T; Tezuka, T | 1 |
| Chen, D; Huang, X; Jin, Z; Liu, Q; Ma, T; Ye, Z | 1 |
1 review(s) available for ym 529 and risedronic acid
| Article | Year |
|---|---|
Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Case-Control Studies; Collagen Type I; Creatinine; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Tartrate-Resistant Acid Phosphatase; Treatment Outcome; Vitamin D | 2020 |
3 trial(s) available for ym 529 and risedronic acid
| Article | Year |
|---|---|
Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease.
Topics: Accidental Falls; Aged; Alzheimer Disease; Body Mass Index; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Risedronic Acid | 2013 |
Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO).
Topics: Aged; Aged, 80 and over; Alendronate; Cross-Over Studies; Demography; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Patient Preference; Risedronic Acid | 2016 |
Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Female; Femur Neck; Hip Joint; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Risedronic Acid | 2018 |
15 other study(ies) available for ym 529 and risedronic acid
| Article | Year |
|---|---|
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats | 2002 |
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Topics: Alkyl and Aryl Transferases; Animals; Cell Division; Cell Line; Diphosphonates; Geranyltranstransferase; Humans; Leishmania major; Lymphocyte Activation; Models, Molecular; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2004 |
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
Topics: Aldose-Ketose Isomerases; Alkyl and Aryl Transferases; Animals; Antiprotozoal Agents; Cell Line; Diphosphonates; Fosfomycin; Geranyltranstransferase; Humans; Mice; Models, Molecular; Multienzyme Complexes; Oxidoreductases; Quantitative Structure-Activity Relationship; Toxoplasma; Toxoplasmosis | 2005 |
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
Topics: Anti-Bacterial Agents; Cluster Analysis; Diphosphonates; Drug Synergism; Escherichia coli K12; Fosfomycin; Gene Expression; Geranyltranstransferase; Models, Molecular; Oligonucleotide Array Sequence Analysis; Quantitative Structure-Activity Relationship; Terpenes | 2006 |
Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases.
Topics: Alkyl and Aryl Transferases; Binding Sites; Crystallography, X-Ray; Dimerization; Diphosphates; Diphosphonates; Diterpenes; Farnesyltranstransferase; Hydrophobic and Hydrophilic Interactions; Isoenzymes; Ligands; Models, Chemical; Models, Molecular; Molecular Structure; Polyisoprenyl Phosphates; Protein Structure, Secondary; Saccharomyces cerevisiae; Sesquiterpenes; Stereoisomerism; Substrate Specificity; Transferases | 2007 |
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.
Topics: Antineoplastic Agents; Crystallography, X-Ray; Diphosphonates; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Farnesyltranstransferase; Humans; K562 Cells; Magnetic Resonance Spectroscopy; Models, Molecular; Quantitative Structure-Activity Relationship | 2008 |
Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
Topics: Alkyl and Aryl Transferases; Bone Density Conservation Agents; Bone Resorption; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Etidronic Acid; Humans; Lactates; Organophosphonates; Organophosphorus Compounds; Osteoporosis; Protein Prenylation; rab GTP-Binding Proteins; Risedronic Acid; Stereoisomerism | 2010 |
Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase.
Topics: Allosteric Site; Catalytic Domain; Diphosphonates; Geranyltranstransferase; Humans; Ligands; Magnesium; Molecular Docking Simulation; Protein Binding | 2015 |
Novel benzimidazole phosphonates as potential inhibitors of protein prenylation.
Topics: Benzimidazoles; Humans; Organophosphonates; Protein Prenylation | 2019 |
Farnesyl pyrophosphate synthase enantiospecificity with a chiral risedronate analog, [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid) (NE-10501): Synthetic, structural, and modeling studies.
Topics: Algorithms; Binding Sites; Bone Density Conservation Agents; Carcinoma; Computer Simulation; Crystallography, X-Ray; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Farnesyltranstransferase; Humans; Imidazoles; Inhibitory Concentration 50; Magnesium; Models, Chemical; Organophosphonates; Pyridines; Risedronic Acid; Stereoisomerism; Structure-Activity Relationship; Zoledronic Acid | 2008 |
[New bisphosphonates and trends in drug therapy for osteoporosis: preface].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Humans; Imidazoles; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2009 |
Gastric ulcerogenic and healing impairment effects of risedronate, a nitrogen-containing bisphosphonate in rats. Comparison with alendronate and minodronate.
Topics: Alendronate; Animals; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Imidazoles; Male; Nitrogen; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stomach Ulcer; Wound Healing | 2011 |
On-cartridge derivatization coupled with solid-phase extraction for the ultra-sensitive determination of minodronic acid in human plasma by LC-MS/MS method.
Topics: Anticoagulants; Area Under Curve; Calibration; Chromatography, Liquid; Diazomethane; Diphosphonates; Humans; Hydrogen-Ion Concentration; Imidazoles; Limit of Detection; Mass Spectrometry; Methylation; Nitrogen; Reproducibility of Results; Risedronic Acid; Solid Phase Extraction; Tandem Mass Spectrometry; Trimethylsilyl Compounds; Zoledronic Acid | 2015 |
Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Drug Substitution; Female; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Patient Preference; Prospective Studies; Risedronic Acid | 2016 |
Location of fractures and the characteristics of patients with atypical femoral fractures: analyses of 38 Japanese cases.
Topics: Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Femoral Fractures; Femur; Glucocorticoids; Humans; Imidazoles; Japan; Male; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Risedronic Acid | 2017 |